The Diagnostic Accuracy of Fecal Calprotectin for Colonoscopic Abnormalities in Patients With Chronic Diarrhea
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70591 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Xinghuang Liu und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Leukocyte L1 Antigen Complex, Diarrhea, Feces, Colonoscopy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: WIZ BIOTECH Co., Ltd. (Xiamen, China), National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
To evaluate the diagnostic accuracy of the colloidal gold immunochromatographic assay‐based fecal calprotectin (CGICA‐FC) for detecting colonoscopic abnormalities in patients with chronic diarrhea.
Methods
We conducted a prospective diagnostic study across 15 centers in China. All patients with chronic diarrhea underwent colonoscopy. We quantitatively measured FC concentrations before bowel preparation and assessed diagnostic performance using ROC curve analysis.
Results
A total of 556 patients with chronic diarrhea and 152 nondiarrhea controls were enrolled. FC levels were significantly higher in patients with Crohn's disease, followed by ulcerative colitis and other inflammation, compared to those with high‐risk adenomas, minor benign findings, normal mucosa, or nondiarrhea controls. For screening colonoscopic abnormalities from nonsignificant findings (normal mucosa & minor benign findings), the optimal cutoff was 93.8 μg/g (AUC = 0.830). FC demonstrated higher discriminatory power for colorectal inflammation (including IBD and other inflammation) with a cutoff of 118.4 μg/g (AUC = 0.896) and was most accurate for identifying IBD specifically (cutoff 157.0 μg/g, AUC = 0.929). However, its accuracy for detecting high‐risk adenomas was limited (AUC = 0.587). FC showed high negative predictive value (NPV = 0.898–0.973) based on the prescreening patients with a low prior probability of abnormalities. Multivariate analysis identified colorectal inflammation and alcohol consumption as independent positive correlates with FC levels, while BMI showed a negative association.
Conclusion
The CGICA‐FC test is an accurate noninvasive tool for triaging patients with chronic diarrhea, with high diagnostic accuracy for identifying colorectal inflammation. Owing to its high NPV, it holds promise for reducing unnecessary colonoscopies in prescreening patients. Chinese Clinical Trial Registry ChiCTR2300070117.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Gastroenterology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China.
- Department of Gastroenterology, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.
- Department of Gastroenterology, the First Affiliated Hospital of Henan Medical University, Xinxiang Key Laboratory of Precision Diagnosis and Treatment for Inflammatory Bowel Disease, Xinxiang, China.
- Department of Gastroenterology, Wuhan Fourth Hospital, Wuhan, China.
- Department of Gastroenterology, The Third People's Hospital of Chengdu, Chengdu, China.
ORCID-Profile: Xinghuang Liu, Xia Tian, Chengdang Wang, Xiaohua Hou
Förderung
- WIZ BIOTECH Co., Ltd. (Xiamen, China)
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Liu, X., Liu, B., Tian, X., Qin, Y., Li, W., Lv, F., Sun, X., Wang, Q., Sun, K., Sun, Y., Xu, P., Wen, Z., Yuan, A., Wang, C., Shi, Z., Fan, Y., Chen, J., Fang, X., Xu, D., …, & Bai, T. (2026). The Diagnostic Accuracy of Fecal Calprotectin for Colonoscopic Abnormalities in Patients With Chronic Diarrhea. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70591
Vancouver
Liu X, Liu B, Tian X, Qin Y, Li W, Lv F, et al. The Diagnostic Accuracy of Fecal Calprotectin for Colonoscopic Abnormalities in Patients With Chronic Diarrhea. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70591
BibTeX
@article{Liu2026,
author = {Liu, Xinghuang and Liu, Binbin and Tian, Xia and Qin, Yongmei and Li, Wenjing and Lv, Fei and Sun, Xiaobin and Wang, Qiong and Sun, Kaidi and Sun, Yueshan and Xu, Ping and Wen, Zhili and Yuan, Anlong and Wang, Chengdang and Shi, Zhihong and Fan, Yanyun and Chen, Junjie and Fang, Xiangming and Xu, Dan and Dai, Chibing and Wu, Kang and Hu, Yunlian and Zhao, Xueying and Zhu, Guoxing and Liang, Liqin and Hou, Xiaohua and Bai, Tao},
title = {The Diagnostic Accuracy of Fecal Calprotectin for Colonoscopic Abnormalities in Patients With Chronic Diarrhea},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70591}
}
EUVIMED